Krysta S. Wolfe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Krysta S. Wolfe has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Bhakti K. Patel
University of Chicago Department of Medicine, Section of Pulmonary and Critical Care Chicago, IL
7 shared publications - John P. Kress
University of Chicago Medicine
4 shared publications Anne S. Pohlman
Department of Medicine, Section of Pulmonary and Critical Care Medicine, University of Chicago Medicine, Chicago, USA
3 shared publicationsJesse B. Hall
Department of Medicine, Section of Pulmonary and Critical Care Medicine, University of Chicago Medicine, Chicago, USA
3 shared publications- Ayodeji Adegunsoye
Department of Medicine, Section of Pulmonary & Critical Care, University of Chicago , Chicago, IL
2 shared publications J.B. Hall
University of Chicago, Chicago, IL, United States
2 shared publications
Latest Publications
- Open Access
- 20 October 2026
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
Eligibility for Early Mobilization in Mechanically Ventilated Adults: A Multicenter Study
Rationale: Early mobilization of mechanically ventilated patients within 72 hours of intubation is underutilized despite its known clinical benefits. The most cited barrier to implementation is physiologic instability. Objectives: To quantify eligibility for early mobilization across established physiologic criteria in a multicenter cohort of mechanically ventilated adults and estimate the relative impact of structural and process implementation barriers. Methods: Retrospective cohort of adults receiving invasive mechanical ventilation for ≥4 hours across nine CLIF Consortium health systems (2018–2024) and MIMIC-IV (2008–2022). Four physiologic eligibility criteria, from clinical trials (Chicago, TEAM) and consensus guidelines (Green, Yellow), were applied between 8am and 5pm within 72 hours of intubation. Random-effects meta-analysis compared eligibility across criteria and quantified the relative effect of two implementation barriers: weekday-only availability (structural) and 4-hour continuous eligibility (process). Measurements and Main Results: Among 223,281 hospitalizations, 86.9–95.6% met eligibility for mobilization within 72 hours of intubation across all 4 criteria. Compared with Chicago trials criteria, eligibility was reduced under TEAM (SHR 0.782, 95% CI 0.746–0.820) and Green (SHR 0.631, 0.611–0.651) but not Yellow (SHR 0.990, 0.976–1.005). Restricting eligibility to weekdays (structural) or requiring continuous eligibility (process) each reduced eligibility by 26-39% across all four criteria (SHR range 0.61–0.74); imposing both barriers together reduced eligibility by 45-56% (SHR range 0.44-0.55). Conclusions: Most mechanically ventilated adults met physiologic eligibility criteria for early mobilization within 72 hours of intubation. Structural and process barriers, such as staff availability on weekends and sustained eligibility for care coordination, reduced opportunity more potently than physiologic instability alone.
- 20 October 2026
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
Open AccessEligibility for Early Mobilization in Mechanically Ventilated Adults: A Multicenter Study
Rationale: Early mobilization of mechanically ventilated patients within 72 hours of intubation is underutilized despite its known clinical benefits. The most cited barrier to implementation is physiologic instability. Objectives: To quantify eligibility for early mobilization across established physiologic criteria in a multicenter cohort of mechanically ventilated adults and estimate the relative impact of structural and process implementation barriers. Methods: Retrospective cohort of adults receiving invasive mechanical ventilation for ≥4 hours across nine CLIF Consortium health systems (2018–2024) and MIMIC-IV (2008–2022). Four physiologic eligibility criteria, from clinical trials (Chicago, TEAM) and consensus guidelines (Green, Yellow), were applied between 8am and 5pm within 72 hours of intubation. Random-effects meta-analysis compared eligibility across criteria and quantified the relative effect of two implementation barriers: weekday-only availability (structural) and 4-hour continuous eligibility (process). Measurements and Main Results: Among 223,281 hospitalizations, 86.9–95.6% met eligibility for mobilization within 72 hours of intubation across all 4 criteria. Compared with Chicago trials criteria, eligibility was reduced under TEAM (SHR 0.782, 95% CI 0.746–0.820) and Green (SHR 0.631, 0.611–0.651) but not Yellow (SHR 0.990, 0.976–1.005). Restricting eligibility to weekdays (structural) or requiring continuous eligibility (process) each reduced eligibility by 26-39% across all four criteria (SHR range 0.61–0.74); imposing both barriers together reduced eligibility by 45-56% (SHR range 0.44-0.55). Conclusions: Most mechanically ventilated adults met physiologic eligibility criteria for early mobilization within 72 hours of intubation. Structural and process barriers, such as staff availability on weekends and sustained eligibility for care coordination, reduced opportunity more potently than physiologic instability alone.
- 10 September 2025
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 53 (11) , e2353-e2355
Innovating the Procedure of Evidence-Based Extubation Through Alternating Cluster-Controlled Trial Design
- 10 September 2025
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 53 (11) , e2353-e2355
Innovating the Procedure of Evidence-Based Extubation Through Alternating Cluster-Controlled Trial Design
- Open Access
- 3 November 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-11
Immunomodulatory fecal metabolites are associated with mortality in COVID-19 patients with respiratory failure
Respiratory failure and mortality from COVID-19 result from virus- and inflammation-induced lung tissue damage. The intestinal microbiome and associated metabolites are implicated in immune responses to respiratory viral infections, however their impact on progression of severe COVID-19 remains unclear. We prospectively enrolled 71 patients with COVID-19 associated critical illness, collected fecal specimens within 3 days of medical intensive care unit admission, defined microbiome compositions by shotgun metagenomic sequencing, and quantified microbiota-derived metabolites (NCT #04552834). Of the 71 patients, 39 survived and 32 died. Mortality was associated with increased representation of Proteobacteria in the fecal microbiota and decreased concentrations of fecal secondary bile acids and desaminotyrosine (DAT). A microbiome metabolic profile (MMP) that accounts for fecal secondary bile acids and desaminotyrosine concentrations was independently associated with progression of respiratory failure leading to mechanical ventilation. Our findings demonstrate that fecal microbiota composition and microbiota-derived metabolite concentrations can predict the trajectory of respiratory function and death in patients with severe SARS-Cov-2 infection and suggest that the gut-lung axis plays an important role in the recovery from COVID-19.
- 3 November 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-11
Open AccessImmunomodulatory fecal metabolites are associated with mortality in COVID-19 patients with respiratory failure
Respiratory failure and mortality from COVID-19 result from virus- and inflammation-induced lung tissue damage. The intestinal microbiome and associated metabolites are implicated in immune responses to respiratory viral infections, however their impact on progression of severe COVID-19 remains unclear. We prospectively enrolled 71 patients with COVID-19 associated critical illness, collected fecal specimens within 3 days of medical intensive care unit admission, defined microbiome compositions by shotgun metagenomic sequencing, and quantified microbiota-derived metabolites (NCT #04552834). Of the 71 patients, 39 survived and 32 died. Mortality was associated with increased representation of Proteobacteria in the fecal microbiota and decreased concentrations of fecal secondary bile acids and desaminotyrosine (DAT). A microbiome metabolic profile (MMP) that accounts for fecal secondary bile acids and desaminotyrosine concentrations was independently associated with progression of respiratory failure leading to mechanical ventilation. Our findings demonstrate that fecal microbiota composition and microbiota-derived metabolite concentrations can predict the trajectory of respiratory function and death in patients with severe SARS-Cov-2 infection and suggest that the gut-lung axis plays an important role in the recovery from COVID-19.
- 2 May 2022
- Published by Oxford University Press (OUP)
- p. A5147
Identification of Clinically Significant Immunologic Profiles in Patients with Septic Shock
- 2 May 2022
- Published by Oxford University Press (OUP)
- p. A5147
Identification of Clinically Significant Immunologic Profiles in Patients with Septic Shock
- Open Access
Outcomes and Cardiovascular Comorbidities in a Predominantly African-American Population with COVID-19
Importance: Racial disparities in COVID-19 outcomes have been amplified during this pandemic and reports on outcomes in African-American (AA) populations, known to have higher rates of cardiovascular (CV) comorbidities, remain limited. Objective: To examine prevalence of comorbidities, rates of hospitalization and survival, and incidence of CV manifestations of COVID-19 in a predominantly AA population in south metropolitan Chicago. Design, Setting, Participants: This was an observational cohort study of COVID-19 patients encountered from March 16 to April 16, 2020 at the University of Chicago. Deidentified data were obtained from an institutional data warehouse. Group comparisons and logistic regression modeling based on baseline demographics, clinical characteristics, laboratory and diagnostic testing was performed. Exposures: COVID-19 was diagnosed by nasopharyngeal swab testing and clinical management was at the discretion of treating physicians. Main Outcomes and Measures: Primary outcomes were hospitalization and in-hospital mortality, and secondary outcomes included incident CV manifestations of COVID-19 in the context of overall cardiology service utilization. Results: During the 30 day study period, 1008 patients tested positive for COVID-19 and 689 had available encounter data. Of these, 596 (87%) were AA and 356 (52%) were hospitalized, of which 319 (90%) were AA. Age > 60 years, tobacco use, BMI >40 kg/m 2 , diabetes mellitus (DM), insulin use, hypertension, chronic kidney disease, coronary artery disease (CAD), and atrial fibrillation (AF) were more common in hospitalized patients. Age > 60 years, tobacco use, CAD, and AF were associated with greater risk of in-hospital mortality along with several elevated initial laboratory markers including troponin, NT-proBNP, blood urea nitrogen, and ferritin. Despite this, cardiac manifestations of COVID-19 were uncommon, coincident with a 69% decrease in cardiology service utilization. For hospitalized patients, median length of stay was 6.2 days (3.4-11.9 days) and mortality was 13%. AA patients were more commonly hospitalized, but without increased mortality. Conclusions and Relevance: In this AA-predominant experience from south metropolitan Chicago, CV comorbidities and chronic diseases were highly prevalent and associated with increased hospitalization and mortality. Insulin-requiring DM and CKD emerged as novel predictors for hospitalization. Despite the highest rate of comorbidities reported to date, CV manifestations of COVID-19 and mortality were relatively low. The unexpectedly low rate of mortality merits further study. KEY POINTS: Questions: What comorbidities are present in African Americans (AA) with COVID-19 and what are the associations with subsequent hospitalization and mortality? What is the incidence of COVID-19-associated cardiac manifestations requiring cardiology service utilization? Findings: In this observational cohort study that included 689 patients with COVID-19 from south metropolitan Chicago (87% AA), cardiovascular (CV) comorbidities were highly prevalent and more common in those that required hospitalization. In addition to AA, age > 60 years, tobacco use, BMI >40 kg/m 2 , diabetes mellitus, hypertension, chronic kidney disease, coronary artery disease (CAD), and atrial fibrillation (AF) were more common in those hospitalized. Age > 60 years, tobacco use, CAD, and AF were associated with in-hospital mortality. Despite this, cardiac manifestations of COVID-19 were uncommon, and cardiology service utilization was low. In-hospital mortality was 13%. AA patients were more commonly hospitalized, but without increased mortality. Meaning: In a predominantly AA population with COVID-19 at a major academic hospital located in south metropolitan Chicago, CV comorbidities were common and were risk factors for hospitalization and death. Although the highest rates of comorbidities to date were present in this cohort, mortality was relatively low and merits further study.
Open AccessOutcomes and Cardiovascular Comorbidities in a Predominantly African-American Population with COVID-19
Importance: Racial disparities in COVID-19 outcomes have been amplified during this pandemic and reports on outcomes in African-American (AA) populations, known to have higher rates of cardiovascular (CV) comorbidities, remain limited. Objective: To examine prevalence of comorbidities, rates of hospitalization and survival, and incidence of CV manifestations of COVID-19 in a predominantly AA population in south metropolitan Chicago. Design, Setting, Participants: This was an observational cohort study of COVID-19 patients encountered from March 16 to April 16, 2020 at the University of Chicago. Deidentified data were obtained from an institutional data warehouse. Group comparisons and logistic regression modeling based on baseline demographics, clinical characteristics, laboratory and diagnostic testing was performed. Exposures: COVID-19 was diagnosed by nasopharyngeal swab testing and clinical management was at the discretion of treating physicians. Main Outcomes and Measures: Primary outcomes were hospitalization and in-hospital mortality, and secondary outcomes included incident CV manifestations of COVID-19 in the context of overall cardiology service utilization. Results: During the 30 day study period, 1008 patients tested positive for COVID-19 and 689 had available encounter data. Of these, 596 (87%) were AA and 356 (52%) were hospitalized, of which 319 (90%) were AA. Age > 60 years, tobacco use, BMI >40 kg/m 2 , diabetes mellitus (DM), insulin use, hypertension, chronic kidney disease, coronary artery disease (CAD), and atrial fibrillation (AF) were more common in hospitalized patients. Age > 60 years, tobacco use, CAD, and AF were associated with greater risk of in-hospital mortality along with several elevated initial laboratory markers including troponin, NT-proBNP, blood urea nitrogen, and ferritin. Despite this, cardiac manifestations of COVID-19 were uncommon, coincident with a 69% decrease in cardiology service utilization. For hospitalized patients, median length of stay was 6.2 days (3.4-11.9 days) and mortality was 13%. AA patients were more commonly hospitalized, but without increased mortality. Conclusions and Relevance: In this AA-predominant experience from south metropolitan Chicago, CV comorbidities and chronic diseases were highly prevalent and associated with increased hospitalization and mortality. Insulin-requiring DM and CKD emerged as novel predictors for hospitalization. Despite the highest rate of comorbidities reported to date, CV manifestations of COVID-19 and mortality were relatively low. The unexpectedly low rate of mortality merits further study. KEY POINTS: Questions: What comorbidities are present in African Americans (AA) with COVID-19 and what are the associations with subsequent hospitalization and mortality? What is the incidence of COVID-19-associated cardiac manifestations requiring cardiology service utilization? Findings: In this observational cohort study that included 689 patients with COVID-19 from south metropolitan Chicago (87% AA), cardiovascular (CV) comorbidities were highly prevalent and more common in those that required hospitalization. In addition to AA, age > 60 years, tobacco use, BMI >40 kg/m 2 , diabetes mellitus, hypertension, chronic kidney disease, coronary artery disease (CAD), and atrial fibrillation (AF) were more common in those hospitalized. Age > 60 years, tobacco use, CAD, and AF were associated with in-hospital mortality. Despite this, cardiac manifestations of COVID-19 were uncommon, and cardiology service utilization was low. In-hospital mortality was 13%. AA patients were more commonly hospitalized, but without increased mortality. Meaning: In a predominantly AA population with COVID-19 at a major academic hospital located in south metropolitan Chicago, CV comorbidities were common and were risk factors for hospitalization and death. Although the highest rates of comorbidities to date were present in this cohort, mortality was relatively low and merits further study.
- Open Access
- 25 May 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-12
Ultrasensitive digital quantification of cytokines and bacteria predicts septic shock outcomes
Quantification of pathogen and host biomarkers is essential for the diagnosis, monitoring, and treatment of infectious diseases. Here, we demonstrate sensitive and rapid quantification of bacterial load and cytokines from human biological samples to generate actionable hypotheses. Our digital assay measures IL-6 and TNF-α proteins, gram-negative (GN) and gram-positive (GP) bacterial DNA, and the antibiotic-resistance gene blaTEM with femtomolar sensitivity. We use our method to characterize bronchoalveolar lavage fluid from patients with asthma, and find elevated GN bacteria and IL-6 levels compared to healthy subjects. We then analyze plasma from patients with septic shock and find that increasing levels of IL-6 and blaTEM are associated with mortality, while decreasing IL-6 levels are associated with recovery. Surprisingly, lower GN bacteria levels are associated with higher probability of death. Applying decision-tree analysis to our measurements, we are able to predict mortality and rate of recovery from septic shock with over 90% accuracy.
- 25 May 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-12
Open AccessUltrasensitive digital quantification of cytokines and bacteria predicts septic shock outcomes
Quantification of pathogen and host biomarkers is essential for the diagnosis, monitoring, and treatment of infectious diseases. Here, we demonstrate sensitive and rapid quantification of bacterial load and cytokines from human biological samples to generate actionable hypotheses. Our digital assay measures IL-6 and TNF-α proteins, gram-negative (GN) and gram-positive (GP) bacterial DNA, and the antibiotic-resistance gene blaTEM with femtomolar sensitivity. We use our method to characterize bronchoalveolar lavage fluid from patients with asthma, and find elevated GN bacteria and IL-6 levels compared to healthy subjects. We then analyze plasma from patients with septic shock and find that increasing levels of IL-6 and blaTEM are associated with mortality, while decreasing IL-6 levels are associated with recovery. Surprisingly, lower GN bacteria levels are associated with higher probability of death. Applying decision-tree analysis to our measurements, we are able to predict mortality and rate of recovery from septic shock with over 90% accuracy.